Módulo 2 – Curso pós-graduado – VIH e Envelhecimento

Non-AIDS Defining Cancers Among HIV Infected People

The epidemiology of non-AIDS defining cancers among HIV infected patients


  1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expec- tancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
  2. Brugnaro P, Morelli E, Cattelan F, et al. Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era. World J Virol. 2015;4:209-18.
  3. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241-8.
  4. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-6.
  5. HIV and aging. A special supplement to the UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013 (http://www.unaids.org/en/ media/unaids/contentassets/documents/unaidspub- lication/2013/20131101_JC2563_hiv-and-aging_en.pdf, accessed 3 May 2016).
  6. TAG. The immune system, HIV and aging. V2. April 2014. (http://www.treat- mentactiongroup.org/ sites/g/files/g450272/f/201404/HIVandAgingV2.pdf, ac- cessed 3 May 2016)
  7. Marin B, Thiébaut R, Bucher HC, et al. Non-AIDS-defining deaths and im- munodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23:1743-53.
  8. Powderly WG. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep. 2012;9:218-22.
  9. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-47.
  10. Wright EJ. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS. 2009;4:447-52.
  11. Justice A, Falutz J. Aging and HIV: an evolving understanding. Curr Opin HIV AIDS. 2014, 9:291-293.
  12. Fisher M, Cooper V. HIV and ageing: premature ageing or premature conclu- sions? Curr Opin Infect Dis. 2012;25:1-3.
  13. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41-50.
  14. Mitsuyasu RT. Non-AIDS-defining cancers. Top Antivir Med. 2014;22:660-5.
  15. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-93.
  16. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Int Med. 2010;153:452-60.
  17. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884-90.
  18. de Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS. 2015;29:2173-81.
  19. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96.
  20. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409-18.
  21. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-63.
  22. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059-67
  23. Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis. 2010;50:1316-21.
  24. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combina- tion antiretroviral therapy. Clin Infect Dis. 2011;52:1458-65.
  25. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipi- ents: a meta-analysis. Lancet. 2007;370:59-67.
  26. Rickabaugh TM, Jamieson BD. A challenge for the future: aging and HIV infec- tion. Immunol Res. 2010;48:59-71.
  27. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association be- tween telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393-5.
  28. Effros RB, Allsopp R, Chiu CP, et al. Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS. 1996;10:F17-22.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018